Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

FDA warns four companies over selling honey tainted with prescription drugs

By Brian Buntz | July 13, 2022

FDA logoFDA has sent warning letters to four companies for illegally marketing honey-based products with unlisted active drug ingredients found in the erectile dysfunction drugs Cialis (tadalafil) and Viagra (sildenafil).

The agency said it confirmed the presence of contaminants in the products through laboratory testing.

The agency sent the warning letters to the following companies:

  • Thirstyrun LLC (also known as US Royal Honey LLC). 
  • MKS Enterprise LLC.
  • Shopaax.com. 
  • 1am USA Incorporated dba Pleasure Products USA.

FDA warned of similarly tainted products in April.

The FDA has asked the above companies to provide responses within 15 working days and a plan for how they will remedy the issue. Companies that fail to satisfy the FDA’s concerns quickly may face legal action, including product seizure or injunction.

In February, the agency released an advisory that several herbal supplements sold on Amazon were tainted with tadalafil and sildenafil, which are phosphodiesterase type 5 (PDE5) inhibitors.

Tadalafil and sildenafil could cause dangerous drops in blood pressure when combined with prescription nitrates like nitroglycerin, isosorbide dinitrate and isosorbide-5-mononitrate, vasodilators commonly used to treat and prevent angina. Some physicians have warned that using nitrates together with erectile dysfunction drugs can lead to cardiovascular collapse.

“Tainted honey-based products like these are dangerous because consumers are likely unaware of the risks associated with the hidden prescription drug ingredients in these products and how they may interact with other drugs and supplements they may take,” FDA Associate Commissioner for Regulatory Affairs Judy McMeekin said in a news release. “Products marketed with unidentified ingredients may be dangerous and, in some cases, deadly to consumers. We encourage consumers to remain vigilant when shopping online or in stores to avoid purchasing products that put their health at risk, and instead seek effective, FDA-approved treatments.”

A June 2022 study published in the Annals of Internal Medicine, however, found that there was no statistically significant association between the co-prescription of nitrates with PDE5 inhibitors and the risk for outcomes including cardiac arrest, myocardial infarction, angina pectoris, and ischemic stroke and syncope. Another study published in 2021 in The Journal of Sexual Medicine reached similar conclusions.

Early reports in the 1990s and 2000s associated the drug Viagra with hundreds of deaths but noted that a cause-and-effect relationship had not been established.

Many medical professionals warn of potential drug-drug interactions associated with combining PDE5 inhibitors and nitrates.

About The Author

Brian Buntz

The pharma and biotech editor of WTWH Media, Brian is a veteran journalist with more than 15 years of experience covering an array of life science topics, including clinical trials, drug discovery and development and medical devices. Before coming to WTWH, he served as content director focused on connected devices at Informa. In addition, Brian covered the medical device sector for 10 years at UBM. At Qmed, he overhauled the brand’s news coverage and helped to grow the site’s traffic volume dramatically. He had previously held managing editor roles on two of the company’s medical device technology publications. Connect with him on LinkedIn or email at [email protected].

Tell Us What You Think! Cancel reply

Related Articles Read More >

kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
Disposable syringe and American currency on black background
PBMs increasingly under fire in drug-pricing battle
Johnson & Johnson logo
Timeline: Navigating Johnson & Johnson’s talc lawsuits and their stock performance impact
pharmaceutical industry. Production line machine conveyor with glass bottles ampoules at factory
5 core trends in drug recalls: An analysis of 2022 and Q1 2023
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2026 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE